Table 2 Summary of studies reporting percent Bland–Altman analysis of interscan variability
Ref. | Population | (n) | Independent variable/subgroup | Bias | lowerLOA | upperLOA |
|---|---|---|---|---|---|---|
[7] | Patients with known pulmonary nodules | |||||
100 | Size: all | − 0,90% | − 16,40% | 14,60% | ||
58 | Size: 30–< 80 mm3 | − 0.3% | − 16.8% | 16.2% | ||
42 | Size: 80–150 mm3 | − 1.7% | − 15.5% | 12.3% | ||
[8] | Patients with pulmonary nodules detected on CCTA | 195 | Cardiac cycle phase (systole vs diastole) | 2.65% | − 47.0% | 52.3% |
[9] | Patients with part− solid nodules | 66 | Kernel | |||
Solid component segmentation | − 3.2% | − 45.0% | 39.0% | |||
Whole nodule segmentation | 13,00% | − 21.0% | 46.0% | |||
[10] | Patients under surveillance for < 2 mm solid nodules | Radiation dose exposure (LDCT vs. ULDCT) | ||||
170 | all nodules | − 2.0% | − 18.0% | 22.7% | ||
97 | indeterminate nodules | − 6.0% | − 12.7% | 21.9% | ||
68 | BMI < 25 | − 2.5% | − 17.5% | 23.6% | ||
102 | BMI > 25 | − 1.0% | − 18.3% | 20.8% | ||
[11] | Patients with preoperative scans for subsolid nodules | 66 | Reconstruction algorithm: FBP vs. MBIR | |||
solid component segmentation | 6.3% | − 51.9% | 64.6% | |||
whole nodule segmentation | 3.2% | − 20.5% | 27,00% | |||
[12] | Patients with emphysema | 88 | Level of inspiration (end-inspiratory vs end-expiratory) | 7,5% | − 24,1% | 39,1% |
[13] | Patients were enrolled prospectively | 105 | Radiation dose (LDCT vs. ULDCT with FBP or SAFIRE) | |||
FBP | 0.2% | − 20.0% | 20.4% | |||
SAFIRE | 0.3% | − 9.7% | 10.4% | |||
[14] | Patients with subsolid nodules | 94 | intraobserver (R1) | − 1,5% | − 17,3% | 16,5% |
Intraobserver (R2) | 0,4% | − 14,8% | 18,5% | |||
[15] | Patients retrospectively enrolled | 202 | Radiation dose exposure (SDCT vs. ULDCT) | |||
Intraobserver (R1) | 1.4% | − 25.1% | 26.2% | |||
Intraobserver (R2) | 1.9% | − 25.1% | 28.9% | |||
Interobserver (R1 vs R2) | 1.2% | − 25,0% | 27.4% | |||
interobserver (R2 vs R1) | 2.1% | − 23.9% | 28.1% | |||
[16] | Consecutive patients referred for known or suspected pulmonary metastases (3.3 mm—30 mm) | 89 | Software | |||
Software A | 0,0% | − 17,0% | 17,0% | |||
Software B | 0,0% | − 13,1% | 13,1% | |||
Software C | 0,0% | − 20,8% | 20,8% | |||
Software D | 0,0% | − 13,4% | 13,4% | |||
Software E | 0,0% | − 20,5% | 20,5% | |||
Software F | 0,0% | − 19,6% | 19,6% | |||
[17] | Patients on follow-up for lung cancer or scanned because of suspicious pulmonary nodules | Radiation dose exposure (SDCT vs. ULDCT) | ||||
229 | Size: all | |||||
Intraobserver (R1) | 1.5% | − 25.1% | 28.1% | |||
Intraobserver (R2) | 2,0% | − 26.4% | 30.4% | |||
Interobserver (R1 vs R2) | 1.3% | − 26.5% | 29.1% | |||
interobserver (R2 vs R1) | 2.2% | − 25.2% | 29.6% | |||
153 | size: < 10 mm | |||||
Intraobserver (R1) | 2.3% | − 28.5% | 33.1% | |||
Intraobserver (R2) | 2.6% | − 29.4% | 34.6% | |||
Interobserver (R1 vs R2) | 1.9% | − 28.3% | 32.1% | |||
Interobserver (R2 vs R1) | 2.1% | − 29,10% | 33.3% | |||
76 | Size: ≥ 10 mm | |||||
Intraobserver (R1) | 1.4% | − 18.6% | 21.4% | |||
Intraobserver (R2) | 0.4% | − 18.6% | 19.4% | |||
Interobserver (R1 vs R2) | 0.4% | − 17,00% | 17.8% | |||
Interobserver (R2 vs R1) | 0.6% | − 18.4% | 19.6% | |||
[18] | Patients with known nodules were prospectively enrolled | 83 | Radiation dose: SDCT vs. LDCT | |||
SDCT | 12.8% | − 27.0% | 40.0% | |||
LDCT | 17.0% | − 38.0% | 60.0% | |||
[19] | Patients with contrast-enhanced chest CT | 101 | Slice thickness: 1 mm | − 0.1% | − 21.6% | 20.3% |
101 | Slice thickness: 3 mm | 1.0% | − 15.4% | 15.2% | ||
101 | Slice thickness: 5 mm | 1.6% | − 21.8% | 27.6% | ||
[20] | Patients with pulmonary metastases | 218 | Segmentation: all | 1.3% | − 21.2% | 23.8% |
106 | Segmentation: complete | 0.28% | − 11.9% | 12.4% | ||
112 | Segmentation: incomplete | 1.61% | − 26.8% | 30.0% | ||
[21] | Patients with pulmonary metastases | 96 | Segmentation algorithm | 0.0% | − 26.9% | 26.9% |
[22] | Patients with pulmonary metastases | 151 | Size: all | 0.7% | − 20.4% | 21.9% |
105 | Size: < 10 mm | 0.55% | − 19.3% | 20.4% |